Barclays Starts Tarsus Pharmaceuticals (TARS) at Overweight

Barclays analyst Glen Santangelo initiates coverage on Tarsus Pharmaceuticals (NASDAQ: TARS) with a Overweight rating and a price target of $100.00.

For an analyst ratings summary and ratings history on Tarsus Pharmaceuticals click here. For more ratings news on Tarsus Pharmaceuticals click here.

Shares of Tarsus Pharmaceuticals closed at $81.77 yesterday.

You May Also Be Interested In

• Tarsus Pharmaceuticals (TARS) PT Raised to $100 at Oppenheimer
• Alliance Global Partners Starts Momentus (MNTS) at Buy
• Raymond James Starts SpyGlass Pharma (SGP) at Outperform